2,6,9-TRISUBSTITUTED PURINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE CATIONIC SALT, METHOD FOR INHIBITION OF CELL PROLIFERATION, PHARMACEUTICAL COMPOSITION Russian patent published in 2004 - IPC

FIELD: organic chemistry, heterocyclic compounds, pharmacy. SUBSTANCE: invention relates to new 2,6,9-trisubstituted derivatives of purine of the general formula (I) eliciting effect of selective inhibitors of kinases in cellular cycle (mitosis). In compounds of the general formula (I) R₁ represents halogen atom or -X wherein X means NH, -O-; represents lower alkyl, substituted lower alkyl comprising from 1 to 3 substituents taken among the group including: group OR²⁰ wherein R²⁰ is hydrogen atom or lower alkyl, aryl, 5-6-membered monocyclic or 8-10-membered bicyclic heteroaryl comprising up to 2 nitrogen heteroatoms in cycle and, optionally, substituted with lower alkyl, mono-, di- or tricyclo--C_3-15-cycloalkyl optionally substituted with group OR²⁰ wherein R²⁰ is hydrogen atom, 5-10-membered heterocyclyl comprising up to 2 heteroatoms in cycle, group NR²⁰SO₂R²¹ wherein R²⁰ is hydrogen atom and R²¹ is phenyl and substituted phenyl comprising from 1 to 3 substituents taken among the group including halogen atom, nitro-group, lower alkyl, trifluoromethyl, lower alkoxy-group, 5-6-membered monocyclic heteroaryl comprising nitrogen or sulfur as heteroatom, group SO₂NR²⁰R²³ wherein R²⁰ and R²³ are hydrogen atom, unsubstituted phenyl or phenyl substituted with halogen atom, lower alkyl, lower alkoxy- group, trifluoromethyl or group CN; cycloalyl comprising 3-10 carbon atoms; 5-10-membered heterocyclyl that can be substituted with benzyl; aryl; substituted phenyl comprising from 1 to 3 substituents taken among the group including halogen atom, nitro-group, lower alkyl, lower alkoxy-group, lower thioalkoxy-group, phenyl, phenoxy-group and phenyl substituted with nitro- -group; and 5-6-membered monocyclic heteroaryl comprising up to 2 heteroatoms taken among nitrogen and sulfur atoms that can be substituted with group OR²⁰ wherein R²⁰ is lower alkyl; R₂ represents hydrogen atom or hydrocarbon comprising 1-20 carbon atoms and taken among the group including: lower alkyl, substituted lower alkyl comprising from 1 to 3 substituents taken among the group including halogen atom, cyano-group, group OR²⁰ wherein R²⁰ is hydrogen atom, group COR²⁰ and group CO₂R²⁰ wherein R²⁰ is lower alkyl or aryl; perfluoroisopropyl; C_3-8-cycloalkyl; lower alkenyl; oleyl; cycloheteroalkyl wherein heterocyclic moiety is taken among epoxymethyl; aryl-lower alkyl and phenyl-lower alkyl substituted with 1-3 substituents in phenyl moiety taken among the group including lower alkyl, nitro-group, group COOR²⁰ wherein R²⁰ is lower alkyl, phenyl and 2-phenylethenyl; R₃ represents hydrogen, halogen atom or group -NR₄R₅, wherein each among R₄ and R₅ is taken among the group including: hydrogen atom; lower alkyl; substituted lower alkyl comprising from 1 to 3 substituents taken among the group including groups: CN, OR²⁰ wherein R²⁰ is hydrogen atom or lower alkyl, COR²⁰ wherein R²⁰ is lower alkoxyalkyl, SR²⁰ wherein R²⁰ is benzyl and others. Invention relates also to pharmaceutically acceptable cationic salt, method for inhibition of cells proliferation and to pharmaceutical composition. Proposed compounds can be used for treatment, for example, autoimmune diseases, such as rheumatic arthritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus (type I), disseminated sclerosis and also for treatment of cancer, cardiovascular diseases, such as restenosis and others. EFFECT: improved inhibition method, valuable medicinal properties of compounds. 52 cl, 10 tbl